Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer
Open Access
- 16 July 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2), e000351
- https://doi.org/10.1136/jitc-2019-000351
Abstract
Background Radiation therapy (RT) has the potential to enhance the efficacy of immunotherapy, such as checkpoint inhibitors, which has dramatically altered the landscape of treatments for many cancers, but not yet for pancreatic ductal adenocarcinoma (PDAC). Our prior studies demonstrated that PD ligand-1 and indoleamine 2,3-dioxygenase 1 (IDO1) were induced on tumor epithelia of PDACs following neoadjuvant therapy including RT, suggesting RT may prime PDAC for PD-1 blockade antibody (αPD-1) or IDO1 inhibitor (IDO1i) treatments. In this study, we investigated the antitumor efficacy of the combination therapies with radiation and PD-1 blockade or IDO1 inhibition or both. Methods We developed and used a mouse syngeneic orthotopic model of PDAC suitable for hypofractionated RT experiments. Results The combination therapy of αPD-1 and RT improved survival. The dual combination of RT/IDO1i and triple combination of RT/αPD-1/IDO1i did not improve survival compared with RT/αPD-1, although all of these combinations offer similar local tumor control. RT/αPD-1 appeared to result in the best systemic interferon-γ response compared with other treatment groups and the highest local expression of immune-activation genes, including Cd28 and Icos. Conclusion Our RT model allows examining the immune-modulatory effects of RT alone and in combination with immune-checkpoint inhibitors in the pancreas/local microenvironment. This study highlights the importance of choosing the appropriate immune-modulatory agents to be combined with RT to tip the balance toward antitumor adaptive immune responses.Keywords
Funding Information
- National Cancer Institute (Gastrointestinal Cancers grant P50 CA062924)
- Bristol-Myers Squibb (BMS II-ON grant)
- Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
- The Viragh Foundation and the Skip Viragh Pancreatic Cancer Center at Johns Hopkins
- National Institutes of Health (R01 CA169702, R01 CA197296)
This publication has 51 references indexed in Scilit:
- Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma TissueJournal of Visualized Experiments, 2013
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II StudyJournal of Clinical Oncology, 2010
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins HospitalJournal of Clinical Oncology, 2008
- Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune DetectionJournal of the American College of Surgeons, 2008
- Adaptive linear step-up procedures that control the false discovery rateBiometrika, 2006
- Combining radiotherapy and immunotherapy: A revived partnershipInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- T cell apoptosis by tryptophan catabolismCell Death & Differentiation, 2002